2022 the Japanese Society of Medical Oncology Annual Meeting

Presentation information

Print

Oral Session

[O13] Oral Session 13　Lung Cancer / Thoracic Cancer 3（Rare gene alterations）
【E】

Sat. Feb 19, 2022 8:20 AM - 9:50 AM Room 1 (Main Hall, 1F, Kyoto International Conference Center)

Chair：Satoshi Oizumi（Department of Respiratory Medicine, National Hospital Organization Hokkaido Cancer Center），Haruyasu Murakami（Chemotherapy Center/Division of Thoracic Oncology, Shizuoka Cancer Center）
Discussant：Takehito Shukuya（Department of Respiratory Medicine, Juntendo University）

[O13-5] Phase 2 trial of crizotinib in Japanese patients with advanced NSCLC harboring a MET gene alteration: Co-MET study

○Ryo Toyozawa1, Kaname Nosaki2, Mototugu Shimokawa3, Hidehito Horinouchi4, Masahiro Morise5, Kadoaki Ohashi6, Haruyasu Murakami7, Miyako Satouchi8, Jun Sakakibara9, Seiji Yano10, Shingo Matsumoto2, Koichi Goto2, Takashi Seto1, Kiyotaka Yoh2 (1.Department of Thoracic Oncology, National Hospital Organization Kyushu Cancer Center, 2.Department of Thoracic Oncology, National Cancer Center Hospital East, 3.Department of Biostatistics, Yamaguchi University Graduate School of Medicine, 4.Department of Thoracic Oncology, National Cancer Center Hospital, 5.Department of Respiratory Medicine, Nagoya University Graduate School of Medicine, 6.Department of Allergy and Respiratory Medicine, Okayama University Hospital, 7.Division of Thoracic Oncology, Shizuoka Cancer Center, 8.Department of Thoracic Oncology, Hyogo Cancer Center, 9.First Department of Medicine, Hokkaido University Hospital, 10.Division of Medical Oncology, Cancer Research Institute, Kanazawa University)

Abstract password authentication.
The password can be found on page 27 of the program book.

Password